Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000491775 | SCV000579677 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2024-09-09 | criteria provided, single submitter | clinical testing | The p.H317R variant (also known as c.950A>G), located in coding exon 6 of the MEN1 gene, results from an A to G substitution at nucleotide position 950. The histidine at codon 317 is replaced by arginine, an amino acid with highly similar properties. This alteration was observed in a proband suspected of having MEN1 with a history of hyperparathyroidism and a carcinoid tumor (Roijers, JF et al. Eur J Clin Invest. 2000 Jun;30(6):487-92). This mutation was also identified in a MEN1 family with at least two affected individuals with a history of primary hyperparathyroidism and/or carcinoid tumors (Wautot, V et al. Hum Mutat. 2002 Jul;20(1):35-47). Of note, this alteration is also designated as c.1060A>G in published literature. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |